Topics: Research
We all wish, hope and work for a ‘cure’ for PWS - new treatments for the hunger, a new therapy to improve behavior, interventions to make our child’s life healthier, happier and more independent. After years with very few new drugs and interventions ...
Just a few short weeks ago, we shared with you the amazing story of Ariana Garagozzo, an aspiring PWS researcher and sister to a young man with PWS. We are pleased to announce that funding for the 2014 Young Investigators Internship Program is comple...
Topics: Research
It’s likely that improper development and/or function of neurons throughout different regions of the brain contributes to many of the characteristics of PWS, including hyperphagia, anxiety, OCD behaviors, sleep disturbances, and temper outbursts. How...
Topics: Research
A recent publication in Science raises a number of interesting questions regarding the potential for prenatal and perinatal (newborn) therapies in the prevention and treatment of autism spectrum disorder (ASD). This type of treatment would be a decad...
Topics: Research
Those with PWS often battle a variety of gastro-intestinal (GI) issues. Beyond general GI function and quality of life, there is a growing field of research exploring how GI composition and health is intricately connected to other systems in the body...
Topics: Research
While the genetic engineering of mouse models has allowed scientists to successfully understand and develop new therapies for many genetic diseases, the PWS mouse models generated so far have not fully mimicked the complexity of human PWS, slowing th...
Topics: Research
In the summer of 1999, Mark Roth and Lauren Schwartz-Roth of Seattle, WA were expecting their first child with great anticipation. However, during the pregnancy, Lauren noticed decreased fetal movement, and when the doctor confirmed that the baby was...
Topics: Stories of Hope
Over 450 excited parents and community members registered for the Clinical Trials Webinar January 19th. Theresa Strong and Jennifer Miller outlined an overview of the drug development process, discussed what you can expect when you participate in a c...
Topics: Research
Zafgen announced in November results of a completed Phase 2 study of their obesity drug, Beloranib, in severely obese patients (non-pws). Findings from the study demonstrated significant weight loss in 147 obese individuals over a 12 weeks of treatme...
Topics: Research